Eich, Hans Theodor; Diehl, Volker; Görgen, Helen; Pabst, Thomas; Markova, Jana; Debus, Jürgen; Ho, Anthony; Dörken, Bernd; Rank, Andreas; Grosu, Anca-Ligia; Wiegel, Thomas; Karstens, Johann Hinrich; Greil, Richard; Willich, Normann; Schmidberger, Heinz; Döhner, Hartmut; Borchmann, Peter; Müller-Hermelink, Hans-Konrad; Müller, Rolf-Peter and Engert, Andreas (2010). Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of clinical oncology, 28(27), pp. 4199-206. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.29.8018
Full text not available from this repository. (Request a copy)Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Pabst, Thomas Niklaus |
ISSN: |
0732-183X |
Publisher: |
American Society of Clinical Oncology |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:09 |
Last Modified: |
02 Mar 2023 23:20 |
Publisher DOI: |
10.1200/JCO.2010.29.8018 |
PubMed ID: |
20713848 |
Web of Science ID: |
000281909700016 |
URI: |
https://boris.unibe.ch/id/eprint/1084 (FactScience: 201831) |
Actions (login required)
 |
Edit item |